Messenger RNA (mRNA) has received great attention in the prevention and treatment of
various diseases due to the success of coronavirus disease 2019 (COVID‐19) mRNA …

RIG-I-like receptors (RLRs) are intracellular pattern recognition receptors that detect viral or
bacterial infection and induce host innate immune responses. The RLRs family comprises …

In late 2020, the US Food and Drug Administration (FDA) approved a lipid-based mRNA
vaccine for the prevention of COVID-19, which has pushed this field to be more closely …

Ionizable lipid‐based nanoparticles (LNPs) are the most advanced non‐viral drug delivery
systems for RNA therapeutics and vaccines. However, cell type‐specific, extrahepatic mRNA …

The introduction of more effective and selective mRNA delivery systems is required for the
advancement of many emerging biomedical technologies including the development of …

Lipid nanoparticles (LNPs) have delivered RNA to hepatocytes in patients, underscoring the
potential impact of nonliver delivery. Scientists can shift LNP tropism to the lung by adding …

Adding a cationic helper lipid to a lipid nanoparticle (LNP) can increase lung delivery and
decrease liver delivery. However, it remains unclear whether charge-dependent tropism is …

Genetically engineered immune cells expressing chimeric antigen receptors (CARs) have
emerged as a new game changer in cancer immunotherapy. The utility of CAR T cell therapy …

Efficient and safe delivery of vulnerable mRNA is a long-standing challenge for the broad
application of the emerging mRNA-based therapeutics. Herein, a combinatorial library …

Lipid nanoparticles (LNPs) are currently the most promising clinical nucleic acids drug
delivery vehicles. LNPs prevent the degradation of cargo nucleic acids during blood …